Developments in Tau PET Imaging.

TitleDevelopments in Tau PET Imaging.
Publication TypeJournal Article
Year of Publication2014
AuthorsZimmer ERigon, Leuzy A, Gauthier S, Rosa-Neto P
JournalCan J Neurol Sci
Volume41
Issue5
Pagination547-53
Date Published2014 Sep
ISSN0317-1671
Abstract

ABSTRACT The presence of neurofibrillary tangles in the brain is a hallmark feature of several neurodegenerative diseases termed "tauopathies," including Alzheimer's disease (AD) and the tau molecular subgroup of frontotemporal lobar degeneration (FTLD-tau). Recently, several positron emission tomography (PET) radiopharmaceuticals targeting abnormal conformations of the tau protein have been developed. To date, six novel tau imaging agents-[18F]THK523, [18F]THK5105, [18F]THK5117, [18F]T807, [18F]T808, and [11C]PBB3-have been described and are considered promising as potential tau radioligands. Tau imaging agents offer the opportunity of in vivo topographical mapping and quantification of tau aggregates in parallel with clinical and cognitive assessments. As such, tau imaging is considered of key importance for progress toward earlier and more accurate diagnosis of tauopathies as well as for the monitoring of therapeutic interventions and drug development. Here, we shed light on the most important developments in tau radiopharmaceuticals, highlighting challenges, possibilities and future directions.

DOI10.1017/cjn.2014.15
Alternate JournalCan J Neurol Sci
PubMed ID25424608
Grant ListMOP-11-51-31 / / Canadian Institutes of Health Research / Canada

  • Douglas Hospital
  • Dobell Pavillion
  • Brain imaging centre